biote Corp.

NasdaqGM BTMD

biote Corp. Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2024: -1.08

biote Corp. Debt to Equity Ratio is -1.08 for the Trailing 12 Months (TTM) ending September 30, 2024, a 59.06% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.

biote Corp. Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2023 was -2.63, a 60.48% change year over year.
biote Corp. Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2022 was -6.66.

Key data

Date	Debt to Equity Ratio	Debt to Income Ratio	Debt to Tangible Net Worth Ratio	Dividend Coverage Ratio

NasdaqGM: BTMD

biote Corp.

CEO	Ms. Teresa S. Weber
IPO Date	April 28, 2021
Location	United States
Headquarters	1875 West Walnut Hill Lane
Employees	194
Sector	Health Care
Industries Pharmaceuticals Biotechnology Drugstores & Retail Pharmacies

Description

biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits for men and women. The company was founded in 2011 and is headquartered in Irvine, Texas.

Key trends

Past 5 years